Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study

Nickenig, Georg; Weber, Marcel; Schüler, Robert; Hausleiter, Jörg; Näbauer, Michael; Bardeleben, Ralph Stephan von; Sotiriou, Efthymios; Schäfer, Ulrich; Deuschl, Florian; Alessandrini, Hannes; Kreidel, Felix; Juliard, Jean‐Michel; Brochet, Éric; Latib, Azeem; Montorfano, Matteo; Agricola, Eustachio; Baldus, Stephan; Friedrichs, Kai; Deo, Shekhar H.; Gilmore, Suzanne Y.; Feldman, Ted; Hahn, Rebecca T.; Maisano, Francesco

doi:10.4244/eij-d-20-01107

Cited by 105 publications

(55 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…437 TTVI are under clinical development. Early registry and study data demonstrated the feasibility to reduce tricuspid regurgitation using various systems, enabling either leaflet approximation ,408,438-440 direct annuloplasty, 409,441 or valve replacement, [442][443][444] with subsequent symptomatic and haemodynamic improvement. 445,446 In a propensity-score-matched study comparing medical treatment to TTVI, all-cause mortality and rehospitalizations at 1 year were lower among the patients who received the interventional treatment.…”

Section: Esc/eacts Guidelinesmentioning

confidence: 99%

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Vahanian¹,

Beyersdorf²,

Praz³

et al. 2022

EuroIntervention

Self Cite

404

581

View full text Add to dashboard Cite

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary. Nor do the ESC Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

show abstract

Section: Esc/eacts Guidelinesmentioning

confidence: 99%

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Vahanian¹,

Beyersdorf²,

Praz³

et al. 2022

EuroIntervention

Self Cite

404

581

View full text Add to dashboard Cite

show abstract

“…The Cardioband™ direct annuloplasty system (Edwards Lifesciences) obtained CE mark for the treatment of patients with severe symptomatic STR in 2018. In the European approval study (TRI-REPAIR), the device -consisting of a screw-anchored adjustable band -was successfully implanted in all 30 patients with sustained reduction of TR to moderate or less in 76% at 30 days, 73% at 6 months 68 and 72% at 2 years 69 , and more than 80% of the patients in NYHA Class I/II throughout the follow-up period. Similarly, a 20% reduction in septolateral diameter was achieved in the post-market core laboratory adjudicated TriBAND study, translating into reduction of TR to moderate or less in 69% of patients at 30 days 70 .…”

Section: Leaflet Approximationmentioning

confidence: 99%

Transcatheter treatment for tricuspid valve disease

Praz¹,

Muraru²,

Kreidel³

et al. 2021

EuroIntervention

Self Cite

156

129

View full text Add to dashboard Cite

“…Exclusion criteria were LV-EF <30%, recent myocardial infarction, unstable angina, or recent coronary intervention, systolic pulmonary pressure > 60 mmHg, moderate or severe regurgitation or stenosis of other heart valves, chronic dialysis, anemia, cardiac cachexia, or life expectancy of less than 12 months. Currently, the follow-up up to 2 years was published [ 7 •].…”

Section: Cardioband Tricuspid Valve Reconstruction Systemmentioning

confidence: 99%

Tricuspid Annuloplasty: Transcatheter Approaches

2021

View full text Add to dashboard Cite

Purpose of Review New transcatheter techniques to perform tricuspid annuloplasty are evolving and are introduced into the clinical routine. Yet, clinical experience is limited. Recent Findings Currently, 3 different techniques for tricuspid annuloplasty have been used in larger clinical cohorts. They can be divided into direct annuloplasty techniques and suture plication techniques. The largest clinical evidence is related to direct annuloplasty techniques. It has been shown that annular dimensions can be effectively reduced. This translates into an improvement of the degree of tricuspid regurgitation and improvement of clinical symptoms. Due to the newness of this type of therapy, long-term data is limited, but for one of the described techniques, published data show that the positive effects persist over a 2-year period. Summary Transcatheter approaches are safe and are able to treat tricuspid regurgitation effectively. There are still differences in the efficacy of the different techniques. Clinical experience varies among the different approaches.

show abstract

Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study

Cited by 105 publications

References 24 publications

2021 ESC/EACTS Guidelines for the management of valvular heart disease

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Transcatheter treatment for tricuspid valve disease

Tricuspid Annuloplasty: Transcatheter Approaches

Contact Info

Product

Resources

About